IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 2133 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (1,249 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures

 Article Access Statistics
    Viewed2244    
    Printed65    
    Emailed2    
    PDF Downloaded101    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
NET LETTER
Year : 2016  |  Volume : 82  |  Issue : 2  |  Page : 239

Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy


Department of Dermatology, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India

Date of Web Publication25-Feb-2016

Correspondence Address:
Ramji Gupta
47-C Pocket B Siddhartha, Extension New Delhi - 110 014
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.174413

Rights and Permissions



How to cite this article:
Gupta R. Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol 2016;82:239

How to cite this URL:
Gupta R. Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol [serial online] 2016 [cited 2017 Sep 24];82:239. Available from: http://www.ijdvl.com/text.asp?2016/82/2/239/174413


Sir,

Prurigo nodularis is a chronic, intensely pruritic nodular condition usually found on the lower extremities, though it can occur anywhere on the body. It was first described by Hardway in 1880 and named by Hyde and Montgomery in 1909. [1] The aetiology of the disease is still not clear. Three types have been described: (i) atopic (ii) non-atopic and (iii) human immunodeficiency virus (HIV) associated. [2] Treatment modalities that have been tried with limited success include antihistamines, topical and intralesional corticosteroids, calcipotriol, capsaicin, thalidomide, lenalidomide, cyclosporine, narrow-band UVB, cryotherapy, pulsed dye laser and recently pregabalin and roxithromycin with tranilast.

Dexamethasone-cyclophosphamide pulse (DCP) therapy has been widely used to treat a large number of autoimmune diseases such as pemphigus, [3] systemic sclerosis [4] and systemic lupus erythematosus [5] with prolonged or permanent remission in several patients. Therapy is administered as 100 mg of dexamethasone dissolved in 500 mL of 5% dextrose, infused over 1-1.5 hours on three consecutive days to which cyclophosphamide 500 mg is added on day 2. These intravenous "pulses" are repeated every 28 days, while oral cyclophosphamide is given daily in a dose of 50 mg. The whole regimen is divided into four phases. [5] Phase I is continued until all lesions clear. In phase II, nine more pulses are given. In phase III, only oral cyclophosphamide is given for 9 months. In phase IV, patients are followed up for any recurrence.

We report three cases of prurigo nodularis unresponsive to various therapies which subsequently responded to Dexamethasone-cyclophosphamide pulse (DCP) therapy. All had itching of unknown aetiology before developing prurigo with no history of atopic dermatitis.

Case 1 was a 41-year-old female with itchy nodules on both legs [Figure 1] and lower back since 15 years. Histopathology was consistent with prurigo nodularis [Figure 2]a and b. Prior intermittent treatment with dapsone, methotrexate, levocetrizine, betamethasone and flucinolone acetonide for 3 years gave mild, transient improvement. Itching disappeared within 15 days after the first Dexamethasone-cyclophosphamide pulse (DCP) pulse and following the second pulse all lesions cleared, leaving behind depigmentation [Figure 3], Subsequently, the patient was administered seven more pulses while remaining asymptomatic. Afterwards, a biopsy showed no signs of prurigo nodularis [Figure 4]. There was no recurrence in a year of follow-up after the last pulse.
Figure 1: Prurigo nodularis, leg before treatment


Click here to view
Figure 2: (a) Prurigo nodularis before treatment (H and E, ×10), (b) Nerve hypertrophy (H and E, ×100)


Click here to view
Figure 3: Prurigo nodularis, leg after treatment


Click here to view
Figure 4: Prurigo nodularis, after treatment (H and E, ×10)


Click here to view


Case 2 was a 71-year-old male with itchy papules all over the body for 2 months. Histopathology supported the diagnosis of prurigo nodularis. There was no improvement after treatment for a month with prednisolone, dapsone, cyproheptadine hydrochloride and topical urea 10%. Dexamethasone-cyclophosphamide pulse (DCP) therapy was started and itching disappeared after the second pulse and lesions after the third pulse. A skin biopsy after the third pulse showed no evidence of prurigo nodularis and the patient discontinued the therapy on his own. However, he developed clinical and histopathological recurrence after 3 months. Pulse therapy was restarted with reduced pruritus and complete clearance of papules following six pulses. Subsequently, he was given seven more pulses and there was no recurrence during 2 years of follow-up.

Case 3 was a 51-year-old male with itchy papules on his legs, arms and abdomen for 1 year. The biopsy findings were consistent with prurigo nodularis. Betamethasone tablets and clobetasol cream were prescribed for a month with no response. Dexamethasone-cyclophosphamide pulse (DCP) pulse therapy was started, with complete clearance of lesions after the third pulse. However, the patient subsequently discontinued the therapy. After 3 months, the condition relapsed and the patient was lost to follow-up.

Many modalities of therapy have been claimed to be effective in clearing lesions of prurigo nodularis but frequently, relapse occurs after discontinuation. With Dexamethasone-cyclophosphamide pulse (DCP) therapy in prurigo nodularis, unlike the classical four-phase regime as given in pemphigus and other autoimmune disorders, response was seen with the initial two to three pulses itself but required seven more pulses to prevent relapse. We infer that Dexamethasone-cyclophosphamide pulse (DCP) therapy could be a valuable therapeutic alternative in cases of prurigo nodularis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Hyde JN, Montgomery F H A. Practical treatise on diseases of the skin for the use of students and practitioners. Philadelphia: Lea and Febiger; 1909 p. 174-5.  Back to cited text no. 1
    
2.
Tanaka M, Aiba S, Matsumura N, Aoyama H, Tagami H. Prurigo nodularis consists of two distinct forms: Early-onset atopic and late-on-set nonatopic. Dermatology 1995;190:269-76.  Back to cited text no. 2
    
3.
Pasricha J S, Dass S S. Curative effect of dexamethasone -cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol 1992;31:875-7.  Back to cited text no. 3
    
4.
Gupta R. Systemic sclerosis treated with dexamethasone pulse. Indian J Dermatol Venereol, Leprol 2003;69:191-2.  Back to cited text no. 4
    
5.
Gupta R, Gupta S, Khera V. Dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus: A case report. J Dermatol Treat 2009;20:55-8.  Back to cited text no. 5
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow